(S (NP-SBJ Peptide/NN vaccination/NN) (VP can/MD (VP lead/VB (PP to/TO (NP enhanced/VBN tumor/NN growth/NN)) (PP through/IN (NP specific/JJ T-cell/NN tolerance/NN induction/NN)))) ./.)
(S (NP-SBJ (NP Vaccination/NN) (PP with/IN (NP (NP synthetic/JJ peptides/NNS) (VP representing/VBG (NP (NP (NP cytotoxic/JJ T/NN lymphocyte/NN) (PRN -LRB-/-LRB- (NP CTL/NN) -RRB-/-RRB-)) epitopes/NNS))))) (VP can/MD (VP lead/VB (PP to/TO (NP (NP a/DT protective/JJ CTL-mediated/JJ immunity/NN) (PP against/IN (NP-COOD (NP tumors/NNS) or/CC (NP viruses/NNS))))))) ./.)
(S (NP-SBJ We/PRP) (ADVP-TMP now/RB) (VP report/VBP (SBAR that/IN (S (NP-SBJ (NP vaccination/NN) (PP with/IN (NP (NP a/DT CTL/NN epitope/NN) (VP derived/VBN (NP */-NONE-) (PP from/IN (NP (NP the/DT human/JJ adenovirus/NN type/NN 5/CD E1A-region/NN) (PRN -LRB-/-LRB- (NP Ad5E1A234-243/NN) -RRB-/-RRB-)))) ,/, (SBAR (WHNP-49 which/WDT) (S (NP-SBJ *T*-49/-NONE-) (VP can/MD (VP serve/VB (PP as/IN (NP (NP a/DT target/NN) (PP for/IN (NP tumor-eradicating/JJ CTL/NN)))))))) ,/,))) (VP (VP-COOD (VP enhances/VBZ (NP *RNR*-50/-NONE-)) (CONJP rather/RB than/IN) (VP inhibits/VBZ (NP *RNR*-50/-NONE-))) (NP-50 (NP the/DT growth/NN) (PP of/IN (NP Ad5E1A-expressing/JJ tumors/NNS))))))) ./.)
(S (NP-SBJ-51 (NP This/DT adverse/JJ effect/NN) (PP of/IN (NP peptide/NN vaccination/NN))) (VP-COOD (VP was/VBD (ADVP-TMP rapidly/RB) (VP evoked/VBN (NP *-51/-NONE-))) ,/, (VP required/VBD (NP (NP (NP low/JJ doses/NNS) (PP of/IN (NP peptide/NN))) (PRN -LRB-/-LRB- (NP 10/CD micrograms/NNS) -RRB-/-RRB-))) ,/, and/CC (VP was/VBD (VP achieved/VBN (NP *-51/-NONE-) (PP by/IN (NP-LGS (NP a/DT mode/NN) (PP of/IN (NP peptide/NN delivery/NN)) (SBAR (WHNP-52 that/WDT) (S (NP-SBJ *T*-52/-NONE-) (VP induces/VBZ (NP protective/JJ T-cell-mediated/JJ immunity/NN) (PP in/IN (NP other/JJ models/NNS)))))))))) ./.)
(S (NP-SBJ-53 Ad5E1A-specific/JJ CTL/NN activity/NN) (VP could/MD (ADVP-TMP no/RB longer/RB) (VP be/VB (VP isolated/VBN (NP *-53/-NONE-) (PP from/IN (NP mice/NNS)) (PP-TMP after/IN (NP (NP injection/NN) (PP of/IN (NP Ad5E1A-peptide/NN)))) ,/, (S (NP-SBJ */-NONE-) (VP indicating/VBG (SBAR that/IN (S (NP-SBJ (NP tolerization/NN) (PP of/IN (NP Ad5E1A-specific/JJ CTL/NN activity/NN))) (VP causes/VBZ (NP the/DT enhanced/VBN tumor/NN outgrowth/NN))))))))) ./.)
(S (PP In/IN contrast/NN to/TO (NP peptide/NN vaccination/NN)) ,/, (NP-SBJ (NP immunization/NN) (PP with/IN (NP (NP adenovirus/NN) ,/, (VP expressing/VBG (NP Ad5E1A/NN)) ,/,))) (VP-COOD (VP induced/VBD (NP Ad5E1A-specific/JJ immunity/NN)) and/CC (VP prevented/VBD (NP (NP the/DT outgrowth/NN) (PP of/IN (NP Ad5E1A-expressing/JJ tumors/NNS))))) ./.)
(S (NP-SBJ These/DT results/NNS) (VP show/VBP (SBAR that/IN (S (NP-SBJ (NP immunization/NN) (PP with/IN (NP synthetic/JJ peptides/NNS))) (VP can/MD (VP lead/VB (PP to/TO (NP (NP the/DT elimination/NN) (PP of/IN (NP anti-tumor/JJ CTL/NN responses/NNS))))))))) ./.)
(S (NP-SBJ These/DT findings/NNS) (VP are/VBP (ADJP-PRD important/JJ (PP for/IN (NP (NP the/DT design/NN) (PP of/IN (NP (NP safe/JJ peptide-based/JJ vaccines/NNS) (PP against/IN (NP-COOD (NP tumors/NNS) ,/, (NP allogeneic/JJ organ/NN transplants/NNS) ,/, and/CC (NP T-cell-mediated/JJ autoimmune/JJ diseases/NNS))))))))) ./.)
